GPCM
WHWK

Granite Point Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Granite Point Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-26,667
Closed -$680K – 137
2018
Q4 		$680K Hold
26,667
– – 0.14% 62
2018
Q3 		$1.24M Sell
26,667
-23,333
-47% -$1.31M 0.08% 74
2018
Q2 		$3.11M Buy
+50,000
New +$3.02M 0.28% 37

Other funds holding WHWK

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NRS
Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return
AIM
Alambic Investment Management Belvedere, California $9.12M AUM 34.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Granite Point Capital Management's WHWK Position: Q1 2019 in Review

Granite Point Capital Management sold out of Whitehawk Therapeutics (WHWK) in Q1 2019, closing a stake of 26,667 shares — an estimated $680K sold.

Granite Point Capital Management first reported a position in WHWK in Q2 2018 and held it in 3 quarters. The position peaked at $3.11M in Q2 2018. 25 funds tracked by Wall St. Rank hold WHWK as of Q1 2019.

  • Granite Point Capital Management reported no remaining Whitehawk Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Granite Point Capital Management sold 26,667 Whitehawk Therapeutics shares in Q1 2019, an estimated $680K.
  • Granite Point Capital Management first reported a position in Whitehawk Therapeutics in Q2 2018 and held it in 3 quarters.
  • Granite Point Capital Management's Whitehawk Therapeutics position peaked at $3.11M in Q2 2018.
  • 25 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2019.

Based on Granite Point Capital Management's 13F filing for Q1 2019, filed 14 May 2019.